DuLac Farmaceutici, an Italian pharmaceutical company with over 30 years of industry experience, is continuing discussions with prospective U.S. retail and distribution partners after participating in the 2026 ECRM Vitamin, Weight Management & Sports Nutrition Session. The event, held September 14-17 in Palm Beach Gardens, Florida, provided a platform for the company to present its Italian-developed portfolio to buyers across health, specialty, food, drug, and mass retail channels. The follow-up conversations are part of DuLac’s broader strategy to build a U.S. retail presence beyond its existing Amazon business.
The company’s portfolio includes high-concentration Arnica Gel 98%, topical leg-care products, and the Dinaven and Diosmin lines. These products reflect DuLac’s Italian manufacturing expertise, botanical formulation capabilities, and pharmaceutical-grade standards. During the ECRM meetings, DuLac introduced buyers to its research and manufacturing approach, including its proprietary Arnica Montana Arricchita™ project and work with botanical ingredients and advanced extraction technologies.
DuLac enters these discussions with an established U.S. e-commerce presence. Its products are already available to American consumers through its Amazon storefront and OneLavi. Customer feedback provides a reference point for prospective partners: the company’s Arnica Gel 98% listing on Amazon.com holds an average customer rating of 4.5 out of 5 stars.
“Our priority following ECRM is to work with prospective partners to identify the DuLac products that best fit their customers and channels,” said Gabriele Bollani, Founder and CEO of DuLac Farmaceutici. “We want to build lasting relationships by combining our Italian formulation and manufacturing expertise with a clear understanding of each partner’s commercial needs.”
The implications of this push are significant for the U.S. retail landscape. DuLac’s move signals growing consumer demand for European-style dermo-cosmetic products and botanical formulations. By leveraging its pharmacy heritage and Italian production, DuLac aims to differentiate itself in a competitive market. The follow-up discussions will focus on product assortment, channel fit, and launch requirements for each prospective partner.
DuLac’s long-term objective is to become a nationally recognized U.S. brand across multiple channels. The company’s existing e-commerce traction, including its 4.5-star Amazon rating, offers evidence of consumer acceptance. As DuLac continues to explore distribution opportunities, its success could pave the way for other international pharmaceutical companies seeking to enter the U.S. market. The company’s ability to translate its Italian expertise into products that resonate with American consumers will be key to its expansion efforts.
